Focused Wealth Management’s United Therapeutics UTHR Stock Holding History

Focused Wealth Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-940	Closed	-$139K	–	747
2017 Q4	$139K	Buy	+940	New	+$119K	0.04%	197
2017 Q3	–	Sell	-940	Closed	-$122K	–	736
2017 Q2	$122K	Hold	940	–	–	0.05%	199
2017 Q1	$127K	Buy	940 +140	+18%	+$21.2K	0.05%	196
2016 Q4	$115K	Buy	+800	New	+$102K	0.05%	209
2016 Q2	–	Sell	-325	Closed	-$36K	–	726
2016 Q1	$36K	Hold	325	–	–	0.02%	234
2015 Q4	$51K	Sell	325 -66	-17%	-$9.61K	0.03%	206
2015 Q3	$51K	Buy	+391	New	+$62.7K	0.03%	196
2015 Q2	–	Sell	-480	Closed	-$86.3K	–	707
2015 Q1	$83K	Buy	+480	New	+$73.2K	0.05%	153

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JIM

Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

Focused Wealth Management's UTHR Position: Q1 2018 in Review

Focused Wealth Management sold out of United Therapeutics (UTHR) in Q1 2018, closing a stake of 940 shares — an estimated $139K sold.

Focused Wealth Management first reported a position in UTHR in Q1 2015 and held it in 8 quarters. The position peaked at $139K in Q4 2017. 374 funds tracked by Wall St. Rank hold UTHR as of Q1 2018.

Focused Wealth Management reported no remaining United Therapeutics position as of Q1 2018 after selling out during the quarter.
Focused Wealth Management sold 940 United Therapeutics shares in Q1 2018, an estimated $139K.
Focused Wealth Management first reported a position in United Therapeutics in Q1 2015 and held it in 8 quarters.
Focused Wealth Management's United Therapeutics position peaked at $139K in Q4 2017.
374 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2018.

Based on Focused Wealth Management's 13F filing for Q1 2018, filed 7 May 2018.